Development and characterization of an indoleamine 2,3-dioxygenase (IDO) deficient mouse model of preeclampsia

被引：0
|
作者：
Santillan, Mark
Pelham, Christopher [1 ]
Ketsawatsomkron, Pimonrat [2 ]
Santillan, Donna
Yang, Baoli
Hunter, Stephen
Sigmund, Curt [2 ]
机构：
[1] Univ Iowa, Dept Mol Physiol & Biophys, Iowa City, IA USA
[2] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA
来源：
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY | 2009年 / 201卷 / 06期
关键词：
D O I：
10.1016/j.ajog.2009.10.783
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
766
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 50 条
  • [1] Synthesis of indoleamine 2,3-dioxygenase (IDO) inhibitor
    Suzuki, Takafumi
    Yokoyama, Yuuaku
    Tsutumi, Katsuhiko
    Yamaguchi, Tomoyuki
    Takikawa, Osamu
    Okuno, Hiroaki
    JOURNAL OF MOLECULAR CATALYSIS B-ENZYMATIC, 2010, 62 (01) : 114 - 115
  • [2] Role of indoleamine 2,3-dioxygenase (IDO) in specific allergen immunotherapy in a mouse model of asthma
    Taher, YA
    Van Esch, ECAM
    Hofman, GA
    Bloksma, N
    Henricks, PAJ
    Van Oosterhout, AJM
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2006, 373 (01) : 98 - 98
  • [3] The indoleamine 2,3-dioxygenase (IDO) pathway controls allergy
    von Bubnoff, D.
    Bieber, T.
    ALLERGY, 2012, 67 (06) : 718 - 725
  • [4] Indoleamine 2,3-dioxygenase (IDO) in inflammation and allergy to Aspergillus
    Romani, Luigina
    Zelante, Teresa
    De Luca, Antonella
    Bozza, Silvia
    Bonifazi, Pierluigi
    Moretti, Silvia
    D'Angelo, Carmen
    Giovannini, Gloria
    Bistoni, Francesco
    Fallarino, Francesca
    Puccetti, Paolo
    MEDICAL MYCOLOGY, 2009, 47 : S154 - S161
  • [5] Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy
    Fujiwara, Yu
    Kato, Shumei
    Nesline, Mary K.
    Conroy, Jeffrey M.
    DePietro, Paul
    Pabla, Sarabjot
    Kurzrock, Razelle
    CANCER TREATMENT REVIEWS, 2022, 110
  • [6] Rapid Development of a Commercial Process for Linrodostat, an Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
    Fraunhoffer, Kenneth J.
    DelMonte, Albert J.
    Beutner, Gregory L.
    Bultman, Michael S.
    Camacho, Kathryn
    Cohen, Benjamin
    Dixon, Darryl D.
    Fan, Yu
    Fanfair, Dayne
    Freitag, Adam J.
    Glace, Andrew W.
    Gonzalez-Bobes, Francisco
    Gujjar, Manjunath
    Haley, Matthew W.
    Hickey, Matthew R.
    Ho, Jeanne
    Iyer, Vidya
    Maity, Prantik
    Patel, Sunil
    Rosso, Victor W.
    Schmidt, Michael A.
    Stevens, Jason M.
    Tan, Yichen
    Wilbert, Christopher
    Young, Ian S.
    Yu, Miao
    ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2019, 23 (11) : 2482 - 2498
  • [7] Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy
    Guo, Yixuan
    Liu, Yu
    Wu, Wei
    Ling, Daishun
    Zhang, Qiao
    Zhao, Peng
    Hu, Xi
    BIOMATERIALS, 2021, 276
  • [8] Activation of brain indoleamine 2,3-dioxygenase (IDO) by cytokines: a model of depressive disorders?
    Moreau, M
    Castanon, N
    Lestage, J
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S80 - S80
  • [9] The therapeutic effect of dendritic cells expressing indoleamine 2,3-dioxygenase (IDO) on an IgA nephropathy mouse model
    Kanghan Liu
    Yiya Yang
    Yinyin Chen
    Shiyao Li
    Yuting Gong
    Yumei Liang
    International Urology and Nephrology, 2020, 52 : 399 - 407
  • [10] Indoleamine 2,3-Dioxygenase (Ido) As A New Immunological Marker In Kidney
    Loiacono, Elisa
    Votta, Barbara
    Amore, Alessandro
    Peruzzi, Licia
    Puccinelli, Maria Paola
    Camilla, Roberta
    Vergano, Luca
    Guido, Giuliana
    Donadi, Maria Elena
    Coppo, Rosanna
    PEDIATRIC NEPHROLOGY, 2013, 28 (08) : 1525 - 1526
12345